Investing for Life

There are major shortcomings in the pharmaceutical industry’s current initiatives to ensure that poor people have access to medicines.

To shore up its own flagging economic performance, the industry is increasingly looking to the potentially huge markets within emerging economies. Yet, poor people who live in these countries still desperately lack affordable and appropriate medicines. The time is ripe for a bold new approach.

The industry must put access to medicines at the heart of its decision-making and practices. This is both a more sustainable long-term business strategy and would allow the industry to better play its role in achieving the universal right to health.